The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified.  In the meantime the

Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion……..    Written by Christine Clark.

Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This

Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of

The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to